AbCellera Biologics Inc.

ABCL · NASDAQ

Official-source baseline for AbCellera Biologics using SEC submissions, SEC company facts, the FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, filed company presentations, and 2026 proxy materials.

Follow Add to Watchlist Ask Question

NASDAQ ABCL Coverage Bootstrap Biotechnology Antibody Therapeutics Clinical-Stage Biotech

Latest ReportMay 13, 2026AbCellera Biologics (ABCL) Coverage Bootstrap: cash-rich clinical-stage antibody platform with ABCL635 catalyst riskView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

ABCLCoverage Bootstrap

Clear tags

MatchAny tag All tags

Latest Thesis

AbCellera Biologics (ABCL) Coverage Bootstrap: cash-rich clinical-stage antibody platform with ABCL635 catalyst risk

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

AbCellera Biologics Inc.Biologics (ABCL) Coverage Bootstrap: cash-rich clinical-stage anMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->